Truist Securities Maintains Buy on HCA Healthcare, Raises Price Target to $390
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald maintains a Buy rating on HCA Healthcare and raises the price target from $375 to $390.
July 24, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst David Macdonald has reaffirmed a Buy rating on HCA Healthcare and increased the price target from $375 to $390.
The reaffirmation of a Buy rating and the increase in the price target from $375 to $390 by Truist Securities is a positive signal for investors. It indicates confidence in HCA Healthcare's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100